EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Discovery of Selective Protein Arginine Methyltransferase 5 Inhibitors in the Management of β-Thalassemia through Computational Methods

Bishant Pokharel iD, Yuvaraj Ravikumar, Lavanyasri Rathinavel iD, Teera Chewonarin iD, Monsicha Pongpom iD, Wachiraporn Tipsuwan, Pimpisid Koonyosying, Somdet Srichairatanakool iD

Molecules · 2024

DOI: 10.3390/molecules29112662 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, 2024. Verfasst von Bishant Pokharel und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand. Hauptthemen laut MEDLINE: Protein-Arginine N-Methyltransferases, beta-Thalassemia, Molecular Dynamics Simulation, Enzyme Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Presidential Ph.D. Scholarship, Chiang Mai University, Thailand, Post-Doctoral Fellowship 2022 (Reinventing University) through Dr. Yuvaraj Ravikumar, Chiang Mai University, Thailand, CMU Faculty of Medicine Fund, Chiang Mai University, Thailand.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

β-Thalassemia is an inherited genetic disorder associated with β-globin chain synthesis, which ultimately becomes anemia. Adenosine-2,3-dialdehyde, by inhibiting arginine methyl transferase 5 (PRMT5), can induce fetal hemoglobin (HbF) levels. Hence, the materialization of PRMT5 inhibitors is considered a promising therapy in the management of β-thalassemia. This study conducted a virtual screening of certain compounds similar to 5′-deoxy-5′methyladenosine (3XV) using the PubChem database. The top 10 compounds were chosen based on the best docking scores, while their interactions with the PRMT5 active site were analyzed. Further, the top two compounds demonstrating the lowest binding energy were subjected to drug-likeness analysis and pharmacokinetic property predictions, followed by molecular dynamics simulation studies. Based on the molecular mechanics Poisson–Boltzmann surface area (MM-PBSA) score and molecular interactions, (3R,4S)-2-(6-aminopurin-9-yl)-5-[(4-ethylcyclohexyl)sulfanylmethyl]oxolane-3,4-diol (TOP1) and 2-(6-Aminopurin-9-yl)-5-[(6-aminopurin-9-yl)methylsulfanylmethyl]oxolane-3,4-diol (TOP2) were identified as potential hit compounds, while TOP1 exhibited higher binding affinity and stabler binding capabilities than TOP2 during molecular dynamics simulation (MDS) analysis. Taken together, the outcomes of our study could aid researchers in identifying promising PRMT5 inhibitors. Moreover, further investigations through in vivo and in vitro experiments would unquestionably confirm that this compound could be employed as a therapeutic drug in the management of β-thalassemia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein-Arginine N-Methyltransferasesbeta-ThalassemiaMolecular Dynamics SimulationEnzyme InhibitorsMolecular Docking SimulationHumansDrug DiscoveryProtein BindingCatalytic DomainAdenosine

Stichwörter der Autor:innen

PRMT5 inhibitorsdynamicsfetal hemoglobinmolecular dockingsimulationsβ-thalassemia

Substanzen

Protein-Arginine N-MethyltransferasesEnzyme InhibitorsPRMT5 protein, humanAdenosine

Autor:innen und Institutionen

  • Department of Biochemistry, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
  • Department of Biotechnology, Mercy College, Palakkad 678006, India.
  • Department of Microbiology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
  • Division of Biochemistry, School of Medical Science, University of Phayao, Phayao 5600, Thailand.

ORCID-Profile: Bishant Pokharel, Lavanyasri Rathinavel, Teera Chewonarin, Monsicha Pongpom, Somdet Srichairatanakool

Förderung

  • Presidential Ph.D. Scholarship, Chiang Mai University, Thailand
  • Post-Doctoral Fellowship 2022 (Reinventing University) through Dr. Yuvaraj Ravikumar, Chiang Mai University, Thailand
  • CMU Faculty of Medicine Fund, Chiang Mai University, Thailand
  • Chiang Mai University, Thailand
  • Presidential Ph.D. Scholarship
  • Post-Doctoral Fellowship 2022 (Reinventing University) through Yuvaraj Ravikumar
  • CMU Graduate School, CMU Faculty of Medicine Fund
  • Chiang Mai University

Zitieren

APA

Pokharel, B., Ravikumar, Y., Rathinavel, L., Chewonarin, T., Pongpom, M., Tipsuwan, W., Koonyosying, P., & Srichairatanakool, S. (2024). The Discovery of Selective Protein Arginine Methyltransferase 5 Inhibitors in the Management of β-Thalassemia through Computational Methods. Molecules. https://doi.org/10.3390/molecules29112662

Vancouver

Pokharel B, Ravikumar Y, Rathinavel L, Chewonarin T, Pongpom M, Tipsuwan W, et al. The Discovery of Selective Protein Arginine Methyltransferase 5 Inhibitors in the Management of β-Thalassemia through Computational Methods. Molecules. 2024. doi:10.3390/molecules29112662

BibTeX
@article{Pokharel2024,
  author = {Pokharel, Bishant and Ravikumar, Yuvaraj and Rathinavel, Lavanyasri and Chewonarin, Teera and Pongpom, Monsicha and Tipsuwan, Wachiraporn and Koonyosying, Pimpisid and Srichairatanakool, Somdet},
  title = {The Discovery of Selective Protein Arginine Methyltransferase 5 Inhibitors in the Management of β-Thalassemia through Computational Methods},
  journal = {Molecules},
  year = {2024},
  doi = {10.3390/molecules29112662}
}
Kostenlos starten →